Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25

Blood

Volumn 108, Issue 3, 2006, Pages 1007-1012

  Zhang, Zhuo ^b   Zhang, Meili ^b   Garmestani, Kayhan ^b   Talanov, Vladimir S ^b   Plascjak, Paul S ^b   Beck, Barbara ^b   Goldman, Carolyn ^b   Brechbiel, Martin W ^b   Waldmann, Thomas A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DIABETES MELLITUS; IMMUNE DEFICIENCY; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LEUKEMIA; TUMOR GROWTH;

EID: 33746644134     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-4757     Document Type: Article

References (32)

1. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia/lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
2. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells, I: production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981;126:1393-1397.
3. Waldmann TA, Greene WC, Sarin PS, et al. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac: monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest. 1984;73:1711-1718.
4. Uchiyama T, Hori T, Tsudo M, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest. 1985;76:446-453.
5. Morris JC, Waldmann TA. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000;59(suppl 1):i109-i114.
6. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701-1712.
7. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-4075.
8. Phillips KE, Herring B, Wilson LA, et al. IL-2Ralpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Cancer Res. 2000;60:6977-6984.
9. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002;100:208-216.
10. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A. 2003;100:1891-1895.
11. Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. 2003;102:284-288.
12. Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63:6453-6457.
13. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002;62:1083-1086.
14. Zhang M, Zhang Z, Goldman CK, Janik J, Waldmann TA. Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood. 2005;105:1231-1236.
15. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. Clin Oncol. 1996;4:1383-1400.
16. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
17. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
18. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-440.
19. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med. 2005;46:199S-204S.
20. Brown I. Astatine-211: its possible applications in cancer therapy. Int J Rad Appl Instrum [A]. 1986;37:789-798.
21. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988;240:1024-1026.
22. Macklis RM, Kaplan WD, Ferrara JL, et al. Alpha particle radio-immunotherapy: animal models and clinical prospects. Int J Radiat Oncol Biol Phys. 1989;16:1377-1387.
23. Vaidyanathan G, Zalutsky MR. Targeted therapy using alpha emitters. Phys Med Biol. 1996;41:1915-1931.
24. Rubin LA, Kurman CC, Biddison WE, Goldman ND, Nelson DL. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma. 1985;4:91-102.
25. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
26. Perera LP, Marques LR, O'Brien AD. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohememarragic Escherichia and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J Clin Microbiol. 1988;26:2127-2131.
27. Schwarz UP, Plascjak P, Beitzel MP, et al. Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. Nucl Med Biol. 1998;25:89-93.
28. Yordanov AT, Garmestani K, Zhang M, et al. Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. Nucl Med Biol. 2001;28:845-856.
29. Kozak RW, Waldmann TA, Atcher RW, Gansow OA. Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry and nuclear science. Trends Biotechnol 1985;4:259-264.
30. Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2004;48:289-296.
31. Wesley JN, McGee EC, Garmestani K, et al. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At. Nucl Med Biol. 2004;31:357-364.
32. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825-2831.